胎儿肾衰竭所致羊水过少的系列羊膜腔灌注后新生儿存活:RAFT临床试验
这项前瞻性非随机临床试验在美国13家胎儿治疗中心纳入32例孕22周前因胎儿肾衰竭(非双侧肾缺如)导致羊水过少的母胎配对,在孕26周前开始系列等渗液体羊膜腔灌注。主要终点为新生儿存活≥14天并放置透析通路,29例活产中19例(65.5%,95%CI 45.7%-82.1%)达到主要终点;存活至出院14例(48%),存活婴儿中7例(64%)在2至5岁间接受肾移植。
要点
- 孕26周前系列羊膜腔灌注可减轻胎儿肾衰竭所致羊水过少的新生儿致死性肺发育不良。
- 29例活产中19例(65.5%)存活≥14天并放置透析通路,14例(48%)存活至出院。
- 接受灌注次数更多、距PPROM间隔更长、孕周>32周及出生体重更高与主要终点存活相关。
核心结论
- 系列羊膜腔灌注可减轻胎儿肾衰竭所致羊水过少新生儿的致死性肺发育不良。
- 仍存在独立于早期肺功能的重要新生儿并发症和死亡。
- 与存活相关的因素与RAFT试验双侧肾缺如队列一致,提示减轻肺发育不良存在共同机制通路。
研究设计与样本
- 报告孕22周前因胎儿肾衰竭(非双侧肾缺如)导致羊水过少的母胎配对结局,存活婴儿数据收集至2026年2月13日。
- 32例参与者在孕26周前开始接受等渗液体系列羊膜腔灌注。
主要发现
- 32例中29例(91%)活产,分娩孕周中位数(IQR)为34周1天(31周5天至34周6天),全部在孕37周前分娩。
- 未发生非预期的严重母体不良事件;最常见母体并发症为未足月胎膜早破19例(56%)和绒毛膜羊膜分离10例(29%)。
- 29例活产新生儿中19例(65.5%,95%CI 45.7%-82.1%)达到主要终点。
- 存活者灌注次数中位数(IQR)为14(9-18)次,非存活者为7(4-11)次(P = .01);存活者首次灌注至PPROM间隔为63.5(60.5-74.5)天,非存活者为29.0(22.0-56.0)天(P = .01)。
- 存活者中孕周>32周占79%,非存活者占38%(P = .03);存活者出生体重中位数(IQR)为2029(1770-2250)g,非存活者为1635(1185-1915)g(P = .01)。
临床怎么用
- 对于孕22周前因胎儿肾衰竭(非双侧肾缺如)导致羊水过少者,可考虑在孕26周前启动系列羊膜腔灌注以减轻致死性肺发育不良。
- 应告知家庭:即使达到主要终点,仍存在独立于早期肺功能的重要新生儿并发症和死亡风险。
- 灌注次数更多、距PPROM间隔更长、孕周>32周及出生体重更高与存活相关,可作为咨询参考。
局限性
- 研究为非随机设计,未设对照组,疗效比较受限。
- 样本量较小(32例参与者),结果需进一步验证。
- 全部参与者均在孕37周前分娩,围产期结局受早产影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anhydramnios from fetal kidney failure causes lethal pulmonary hypoplasia. Serial amnioinfusions have shown promise in mitigating pulmonary disease from bilateral renal agenesis, but efficacy and safety for other causes of fetal kidney failure are unproven. OBJECTIVE: To assess the efficacy of serial amnioinfusions initiated before 26 weeks' gestation to mitigate lethal pulmonary hypoplasia in cases of anhydramnios due to fetal kidney failure. DESIGN, SETTING, AND PARTICIPANTS: Prospective, nonrandomized clinical trial conducted at 13 US fetal therapy centers from December 2018 to February 2025. Outcomes for maternal-fetal pairs with anhydramnios before 22 weeks' gestation due to fetal kidney failure without bilateral renal agenesis are reported; data collection for surviving infants continued until February 13, 2026. EXPOSURE: Thirty-two participants underwent serial amnioinfusions with isotonic fluid beginning before 26 weeks' gestation. MAIN OUTCOMES AND MEASURES: The primary end point was neonatal survival for 14 days or longer with dialysis access placement. Secondary outcome measures of survival to discharge home and kidney transplant are reported. RESULTS: Twenty-nine of 32 participants (91%) had a live birth, with a median (IQR) gestational age at delivery of 34 weeks 1 day (31 weeks 5 days to 34 weeks 6 days). All participants delivered before 37 weeks' gestation. No unexpected serious maternal adverse events occurred, and the most common maternal complications were preterm prelabor rupture of membranes in 19 participants (56%) and chorioamniotic separation in 10 (29%). The primary outcome occurred in 19 (65.5%) of 29 live-born neonates (95% CI, 45.7%-82.1%). Factors associated with survival to the primary outcome included receiving more amnioinfusions (median [IQR], 14 [9-18] in survivors vs 7 [4-11] in nonsurvivors; P = .01), longer time interval from first amnioinfusion to preterm prelabor rupture of membranes (63.5 [60.5-74.5] days in survivors vs 29.0 [22.0-56.0] days in nonsurvivors; P = .01), gestational age greater than 32 weeks (79% of survivors vs 38% of nonsurvivors; P = .03), and higher birth weight (2029 [1770-2250] g in survivors vs 1635 [1185-1915] g in nonsurvivors; P = .01). Fourteen live-born infants (48%) survived to hospital discharge at a median (IQR) age of 4.7 (3.4-5.7) months. Of the 11 infants surviving to date, 7 (64%) have undergone kidney transplant between ages 2 years to 5 years. CONCLUSIONS AND RELEVANCE: Serial amnioinfusions mitigated lethal pulmonary hypoplasia in neonates with anhydramnios due to fetal kidney failure. Significant neonatal morbidity and mortality independent of early lung function was noted. Factors associated with survival were consistent with the Renal Anhydramnios Fetal Therapy trial's bilateral renal agenesis cohort, suggesting common mechanistic pathways for mitigating pulmonary hypoplasia. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03101891.
引用
- Miller JL, Baschat AA, Johnson A, et al. Neonatal Survival After Serial Amnioinfusions for Anhydramnios Due to Fetal Kidney Failure: The RAFT Clinical Trial. JAMA. 2026. PMID: 42384373. doi:10.1001/jama.2026.8568
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。